drugset / Trial / NCT02034279

The INFECIR-2 Albumin Prevention Study

NCT02034279

Phase 4 Terminated 136 enrolled EASL - CLIF Consortium
RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study is to evaluate whether albumin administration improves short-term survival in patients with advanced cirrhosis and bacterial infections other than Spontaneous Bacterial Peritonitis (SBP).

Timeline

Start
2014-05
Primary completion
2016-12-31
Completion
2017-02-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Albumin Protein / enzyme biologic 20 % Intravenous